Advice

Following a resubmission.

Omalizumab (Xolair®) is not recommended for use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma.

The economic case has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Download detailed advice88KB (PDF)

Download

Medicine details

Medicine name:
omalizumab 150mg powder and solvent for injection (Xolair)
SMC ID:
259/06
Indication:
Asthma
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Resubmission
Status
Superseded
Date advice published
15 January 2007